Archynetys Live news trend intelligence
◼ Archived Health 🔮 Archynetys predicts: fades by tomorrow — graded ✗ wrong

Common Hormonal Contraceptive Linked to Risk of Rare Brain Tumor

Reports and regulatory meetings are highlighting a potential link between a common hormonal contraceptive and rare brain tumors.

By · Published July 14, 2026 at 08:47 UTC · Updated July 14, 2026 at 19:29 UTC

6sources
6articles
4velocity
+0%since first seen
60d agofirst detected

Evidence dossier

Intelligence passport

65/100 Strong
6distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 4.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.
  5. Outcome review added Archynetys revisited the signal after coverage cooled.

Source diversity sample: New York Post · Yahoo News UK · The Independent · Daily Record · European Medicines Agency (EMA) · ScienceAlert.

How this dossier is built: methodology · AI policy · corrections.

📍 How it ended

Reports linked a common hormonal contraceptive, including the Depo-Provera jab, to the risk of rare brain tumors. Victims called for risk warnings and updated drug guidance from NHS Scotland.

The story quieted without a definitive conclusion in the coverage.

Epilogue added 57d ago, after coverage quieted.

The obvious questions

Which contraceptive is being linked to brain tumors?

Coverage specifically identifies the Depo-Provera contraceptive jab.

What actions are being called for in the UK?

Calls have been made for NHS Scotland to update drug guidance and for risk warnings to be provided to women.

Which regulatory body has discussed this issue?

The European Medicines Agency (EMA) via its Pharmacovigilance Risk Assessment Committee (PRAC).

The story so far

⚡ Executive Intelligence Takeaways Corroborated across 6 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 6 distinct news outlets with 6 published articles, achieving a live velocity of 4.
  • Primary Driver: Reports and regulatory meetings are highlighting a potential link between a common hormonal contraceptive and rare brain tumors.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

Recent coverage indicates that a hormonal contraceptive, specifically the Depo-Provera jab, is being linked to the risk of rare brain tumors. Some individuals report receiving inoperable tumors following the use of the contraceptive.

Reports from ScienceAlert and the New York Post focus on the medical link, while the Independent and Daily Record highlight testimonies from victims. In the UK, there are calls for NHS Scotland to update drug guidance and for the implementation of risk warnings for women.

The European Medicines Agency (EMA) has addressed this through meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) held July 6-9, 2026. Further developments will depend on these regulatory reviews and updated medical guidance.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 57d ago.

Coverage (6)

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

Depo-Provera EMA NHS Scotland Brain Tumors Hormonal Contraceptives

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →